Citation: Kumar V, Hertz M, Agro A and Byrne AJ (2023) Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis. Front. Immunol. 14:1260503. doi: 10.3389/fimmu.2023.1260503 Chronic tissue inflammation often results in fibrosis characterized by the accumulation of extracellular matrix components remodeling normal tissue architecture and function. Recent studies have suggested common immune mechanisms despite […]
Category: Lung diseases
Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosisand type 2 diabetes mellitus: a national claims‑based cohort analysis
Abstract BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high morbidity and limited treatment options. Type 2 diabetes mellitus (T2DM) is a common comorbid illness among patients with IPF and is often treated with metformin, the first-line agent in the management of T2DM. There is growing evidence demonstrating metformin’s anti-fibrotic properties; however, […]
TIPAL
TIPAL: The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole, a randomised placebo-controlled multi-centre clinical trial The TIPAL research study is focusing on treating idiopathic pulmonary fibrosis (IPF) with the addition of lansoprazole. Lansoprazole reduces the amount of acid your stomach makes. It’s used for indigestion, heartburn, acid reflux and gastroesophageal-reflux-disease (GORD). Lansoprazole is […]
Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling
Abstract The mitochondrial calcium uniporter (MCU) regulates metabolic reprogramming in lung macrophages and the progression of pulmonary fibrosis. Fibrosis progression is associated with apoptosis resistance in lung macrophages; however, the mechanism(s) by which apoptosis resistance occurs is poorly understood. Here, we found a marked increase in mitochondrial B-cell lymphoma-2 (Bcl-2) in lung macrophages from subjects […]
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat Toby M. Maher1,2* and Mary E. Strek3 Correspondence: t.maher@rbht.nhs.uk1National Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London,SW3 6NP, UK2Fibrosis Research Group, National Heart and Lung Institute, Imperial College, Cale Street, London SW3 6LY, UKFull list of […]
Mitochondrial Quality Control in COPD and IPF
Mitochondrial Quality Control in COPD and IPF Hiromichi Hara * ID , Kazuyoshi Kuwano and Jun Araya Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine,Tokyo 105-8461, Japan; kkuwano@jikei.ac.jp (K.K.); araya@jikei.ac.jp (J.A.)Correspondence: hirohara@jikei.ac.jp; Tel.: +81-3-3433-1111; Fax: +81-3-3433-1020Published: 24 July 2018 Abstract: Mitochondria play important roles in the maintenance of intracellular […]